13F Holdings
中文EN

RAPH Raphael Pharmaceutical Inc.

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1415397 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY33.4%
TTM EPS YoY-37.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-5,297.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets27,028.6%
Debt / equity—
Current ratio0.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.02x
Accruals ratio-5,216.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-30
Income statement
Revenue————————
R&D expense$40,000$37,000$345,000$73,000$141,000$72,000$211,000$162,000
SG&A expense$159,000$186,000-$91,000$178,000$174,000$353,000$183,000$157,000
Operating income-$199,000-$223,000-$254,000-$251,000-$315,000-$425,000-$394,000-$319,000
Interest expense—$3,000——————
Net income-$223,000-$229,000-$273,000-$255,000-$322,000-$429,000-$395,000-$326,000
EPS (basic)0.010.01—0.010.020.02—0.01
EPS (diluted)0.010.01—0.010.020.02—0.01
Weighted avg. shares (diluted)20.18M20.18M—19.63M19.63M19.63M—18.70M
Balance sheet
Cash & equivalents$1,000$1,000$45,000$3,000$20,000$50,000$19,000$40,000
Receivables——$2,000———$2,000—
Current assets$6,000$1,000$51,000$5,000$28,000$91,000$25,000$49,000
PP&E, net$1,000$2,000$2,000$2,000$2,000$2,000$2,000$2,000
Total assets$7,000$3,000$53,000$7,000$30,000$93,000$27,000$51,000
Current liabilities$1.89M$1.67M$1.49M$1.27M$1.08M$827,000$769,000$667,000
Short-term debt——————$41,000—
Total liabilities$1.89M$1.67M$1.49M$1.27M$1.08M$827,000$769,000$667,000
Shareholders' equity-$1.89M-$1.66M-$1.43M-$1.26M-$1.05M-$734,000-$742,000-$616,000
Shares outstanding20.18M20.18M20.18M19.63M19.63M19.63M18.70M18.70M
Cash flow statement
Operating cash flow$0-$44,000$46,000-$17,000-$30,000-$209,000-$62,000-$80,000
Financing cash flow——-$4,000$0$0$240,000$41,000$0
Stock-based compensation——$1,000$39,000$8,000$197,000$289,000$0

Free plan shows the latest 8 periods; Pro shows all 24 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.